The thyroid gland disorder treatment market was valued at USD 2.25 Billion in 2025, driven by the growing investments in the treatment of thyroid disorders across 8 major markets. The market is anticipated to grow at a CAGR of 3.10% during the forecast period of 2026-2035 to achieve a value of USD 3.05 Billion by 2035. The rise in awareness around the condition, along with the focus on early diagnosis also contribute to the market growth.
Base Year
Historical Period
Forecast Period
Growing sedentary lifestyles and dietary imbalances are contributing to a rising global incidence of thyroid gland disorders.
Increasing healthcare access and diagnostic advancements are enabling earlier detection and timely treatment of thyroid conditions.
Expanding awareness campaigns and supportive government initiatives are boosting demand for long-term thyroid disorder management therapies.
Compound Annual Growth Rate
3.1%
Value in USD Billion
2026-2035
*this image is indicative*
Thyroid gland disorder treatment involves managing conditions such as hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. It includes medications like levothyroxine, antithyroid drugs, radioactive iodine therapy, and surgical interventions. The goal is to restore hormonal balance, alleviate symptoms, and prevent complications. The prevalence of hypothyroidism (HT) in the United States rose from 9.5% in 2012 to 11.7% in 2019, with over 78% of patients receiving thyroxine (T4) monotherapy. The NHANES dataset confirmed that T4 replacement therapy remains the most commonly used treatment for HT. During the same period, the proportion of patients with untreated HT increased from 11.8% to 14.4%. Treatment is tailored to the disorder type and patient’s condition, often requiring lifelong monitoring to ensure effective thyroid function and improved quality of life. The market is expected to grow at a CAGR of 3.10% during the forecast period of 2026-2035.
Regulatory Approvals Enhancing Market Growth
Rising demand for targeted, nonsurgical therapies and the growing focus on autoimmune thyroid-related conditions are transforming treatment protocols. For instance, in September 2024, Japan’s Ministry of Health approved a biologic therapy for active Thyroid Eye Disease (TED), marking the first such approval in Asia. The therapy offers a nonsurgical, nonsteroidal option to treat the root cause of TED. This development is expected to significantly improve access to advanced treatments across Asia, expanding the market in the forecast period through increased adoption and reduced dependence on invasive interventions.
Molecular Advancements to Drive Thyroid Gland Disorder Treatment Market Value
Precision oncology and pediatric inclusivity in thyroid cancer care are emerging as strong growth drivers in the market. For instance, in September 2024, the FDA granted full approval for selpercatinib, a targeted RET inhibitor, to treat advanced or metastatic RET-mutant medullary thyroid cancer in both adults and children aged two and older. The approval was based on robust Phase 3 trial results showing a 72% reduction in disease progression risk. This breakthrough is poised to drive substantial market growth by encouraging the adoption of molecular diagnostics and targeted therapies for thyroid malignancies in the upcoming years.
Some of the notable trends include an increase in collaborative initiatives between leading companies and academic institutions, growing preference for personalized treatments and adoption of digital health tools in the market.
Thyroid Gland Disorder Treatment Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Hypothyroidism to Lead the Segmentation by Type
Hypothyroidism is expected to hold the largest market share due to its rising global prevalence, especially among women and the elderly. As per the analysis by Expert Market Research, the hypothyroidism market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034. With increasing awareness, improved diagnostics, and higher screening rates, more patients are being diagnosed early. The chronic nature of the condition demands lifelong hormone replacement therapy, driving consistent product demand. This segment’s strong therapeutic pipeline and high patient base position it as a key contributor to the thyroid gland disorder treatment market’s future expansion.
Levothyroxine to Hold a Significant Thyroid Gland Disorder Treatment Market Value for Segmentation by Treatment
Levothyroxine is anticipated to dominate the treatment segment as it remains the gold standard for managing hypothyroidism. Its long-standing clinical efficacy, affordability, and wide availability contribute to its continued preference among healthcare professionals. Rising diagnosis rates and long-term patient dependency support growing prescription volumes. Additionally, the drug’s inclusion in essential medicine lists globally strengthens its role in ensuring market growth during the forecast period.
A 2024 study conducted at the Outpatient Department of the National Institute of Unani Medicine in Bengaluru, India, reported a 7% prevalence of hypothyroidism in the study population, with 4% of cases self-reported and 3% previously undiagnosed. Additionally, 4% of participants were found to have subclinical hypothyroidism. These findings highlight the growing burden of thyroid disorders in India and support the country’s emerging role in the hypothyroidism treatment market.
The United States is expected to continue leading the market due to its high hypothyroidism prevalence, comprehensive screening programs, and strong access to specialized endocrine care. Japan maintains a significant share, supported by an aging population that is more susceptible to thyroid dysfunction. In Europe, countries like Germany and France benefit from universal healthcare systems that provide consistent coverage for chronic thyroid conditions.
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
AbbVie Inc., headquartered in North Chicago, Illinois, was founded in 2013 after its separation from Abbott Laboratories. The company offers a diverse portfolio in specialty pharmaceuticals, including treatments for endocrine disorders. In the thyroid gland disorder treatment market, AbbVie is known for providing hormone therapies, particularly levothyroxine-based solutions, aimed at managing hypothyroidism and related conditions effectively.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology firm specializing in innovative therapies. While primarily focused on oncology and nephrology, Amgen supports thyroid gland disorder treatment through research and biological therapies that address hormone imbalances and autoimmune-related thyroid diseases, aligning with its broader endocrine and metabolic disorder solutions.
GSK Plc, a British multinational headquartered in London and founded in 2000 through a merger, focuses on pharmaceuticals, vaccines, and consumer healthcare. In the thyroid gland disorder treatment market, GSK provides therapies that target autoimmune conditions like Graves’ disease and thyrotoxicosis. Its extensive R&D capabilities contribute to advancements in hormone regulation and thyroid-related metabolic treatment options.
Merck KGaA, based in Darmstadt, Germany, and founded in 1668, is a science and technology leader with a strong pharmaceutical portfolio. In the thyroid disorder treatment market, Merck offers levothyroxine-based medications and supports research on hormonal imbalances and thyroid cancer. Its legacy in endocrinology has made it a key player in addressing thyroid dysfunction globally.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Viatris Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Elexis Inc., and IBSA Pharma (IBSA Group).
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share